Effects of the Oral Converting Enzyme Inhibitor, SQ 14225, in a Model of Low Cardiac Output in Dogs

    loading  Checking for direct PDF access through Ovid



Dogs with thoracic caval constriction retain sodium and develop ascites and edema. The role of the renin-angiotensin-aldosterone system in this model of low output failure was evaluated before, during, and after administration of the new orally active converting enzyme inhibitor, 2-D-methyl-3-mercaptopropanoyl-L-proline (SQ 14225). The acute response to the initial oral dose of SQ 14225 (10 mg/kg) consisted of a striking fall in plasma aldosterone concentration (PAC) from 22.7 and 29.9 ng% to 10.7, 11.9, and 11.0 ng% (P < 0.05) after 67.5, 112.5, and 157.5 minutes; sodium excretion increased from 1.9 and 1.9 μEq/min to 19.9, 22.4, and 17.8 μEq/min. Arterial pressure and filtration fraction decreased (P< 0.05), and plasma renin activity (PRA) increased (P < 0.05) after the initial dose of SQ 14225; clearance of para-aminohippuric acid (PAH) and creatinine did not change significantly. The daily responses for 3-4 days to SQ 14225 (35 mg/kg per day, given as doses of 10,10, and 15 mg/kg) were a decrease in PAC from 50 ± 15 and 32 ± 10 ng% to 10 ± 4 ng% on the 4th day, a value not statistically different from normal (P > 0.05), and an increase in sodium excretion from 2.9 to 2.0 mEq/ day to 5.7, 10.0, 32.4, and 32.9 mEq/day on a sodium intake of 35 mEq/day (P < 0.05 for the last 2 days). Arterial pressure and creatinine clearance decreased (P < 0.05). PRA increased transiently on day 1 of SQ 14225 and then returned toward control levels, and clearance of PAH was unchanged. These data demonstrate an important role for aldosterone and the renin-angiotensin system in the retention of sodium and in ascites formation in dogs with thoracic caval constriction. Circ Res. 45: 540-545, 1979

Related Topics

    loading  Loading Related Articles